Cite
HARVARD Citation
Hanley, M. et al. (2023). A Phase 1 Drug‐Drug Interaction Study Between Brigatinib and the CYP3A Substrate Midazolam in Patients With ALK‐Positive or ROS1‐Positive Solid Tumors. Journal of clinical pharmacology. pp. 583-592. [Online].